Roger D. Nolan

Roger Nolan is responsible for the development of BioKier’s drug candidates for type 2 diabetes, including capital-raising, preclinical, clinical and regulatory strategy, and management of consultant and strategic partner interactions.

Dr. Nolan is experienced in management of preclinical and clinical drug development programs, regulatory strategy and interactions, evaluation of new technologies for in-licensing, and outsourcing to specialist service providers. His specific areas of expertise are in diabetes, oncology and cardiovascular indications.

Previous positions held by Dr. Nolan include Senior Director, Science and Technology Evaluation for Calvert Research, Senior Scientist in Clinical Development at Cato Research, and Director Pharmacology at Insmed Pharmaceuticals.

Dr. Nolan started his career at Eastern Virginia Medical School where he had a joint appointment in Biochemistry and Internal Medicine and conducted basic and clinical research at the Strelitz Diabetes Research Center. He received a PhD in Pharmacology and Biochemistry from Melbourne University and completed Postdoctorate fellowships at the National Institute of Environmental Health Sciences and at Burroughs Wellcome.